Home > Expanded Access > Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Eli Lilly and Company

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Official Title: 
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
Brief Summary: 
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Available
EA Type
Individual Patients
Metastatic Breast Cancer

Drug: Abemaciclib
Administered orally.
Other Name: LY2835219

Eligibility Criteria: 

Inclusion Criteria:

- Patients with hormone receptor positive metastatic breast cancer for whom there is reasonable expectation that abemaciclib may provide clinical benefit and who are suitable to receive abemaciclib.

Eligibility Gender: 
All
Eligibility Age: 
Minimum: 18 Years
Countries: 
Australia, Canada, Egypt, Italy, Korea, Republic of, Malaysia, Singapore, South Africa, Spain, Switzerland, Taiwan, United Kingdom
Contacts: 

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
clinicaltrials.gov@lilly.com

Eli Lilly and Company
EA Number: 
MeSH Terms: 
Breast Neoplasms
Disclaimer:
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.